[Clinical utility of the measurement of vitamin D]

Haute Autorité de Santé
Record ID 32016000247
Authors' objectives: A very large number of epidemiological and interventional studies have observed the existence of a link between vitamin D and certain diseases, both bone diseases and non-bone diseases. In parallel, the number of measurements of 25(OH)D performed in France has increased considerably over about the last 10 years, becoming the largest item of expenditure in relation to laboratory tests. Therefore, the question of the clinical utility of this measurement has been raised. In this work, it was proposed that the measurement would be considered useful i) if the link between vitamin D and disease has been demonstrated, ii) if it is possible to define the therapeutic threshold for the concentration of 25(OH)D, and iii) if prior measurement would improve the clinical results of vitamin D supplementation. A positive response to these three questions would justify the measurement of 25(OH)D.
Authors' recomendations: • In response to the first question of the assessment, neither the literature data nor the opinion of the WG establishes an association between vitamin D and mortality, bone mineral density in healthy children and adolescents, breast cancer, prostate cancer or cystic fibrosis. • In response to the second question, in the remaining situations studied, neither the literature data nor the opinion of the WG permits the definition of the therapeutic target for an improvement of the clinical signs or for risk reduction in the following situations: falls, functional performances, colorectal cancer, arterial hypertension, cardiovascular diseases, allergies, autoimmune diseases, type 2 diabetes, chronic renal failure, adverse events during pregnancy, infectious diseases, cognitive performances or lipid profile. In relation to the risk of fracture, an observational study seems to indicate that a threshold concentration of vitamin D of at least 60 nmol/l would be necessary to observe a protective effect in a population aged over 65. Because of the existence of a threshold of this type, the working group considered that it could be useful to determine vitamin D in patients with chronic illness that cause a shortage or deficiency of vitamin D, patients with osteoporosis, or patients with a disease or undergoing a treatment that induces osteoporosis. Nevertheless, the beneficial effect of supplementation reported in the literature related to a very limited population (elderly population at risk of fracture – low bone mineral density or osteoporosis – or an elderly population in institutional care). Furthermore, this value of 60 nmol/l came from a single observational study. • In response to the third question, in the only situation that has been studied that remains at this stage, that is to say, the risk of fracture, no literature data have been identified, so it is not possible to respond positively to this question. In all the situations analysed in this assessment, the data analysed fail to demonstrate the clinical utility of the measurement of vitamin D.
Project Status: Completed
Year Published: 2013
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: France
MeSH Terms
  • Humans
  • Cholestanes
  • Vitamin D
  • Vitamins
Organisation Name: Haute Autorité de Santé
Contact Address: 2 avenue du Stade de France, 93218 Saint-Denis La Plaine Cedex, France. Tel: +33 01 55 93 71 88; Fax: +33 01 55 93 74 35;
Contact Name: sh.leerobin@has-Sante.fr
Contact Email: sh.leerobin@has-Sante.fr
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.